PR 2018

Press Releases | 2018

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.

Press Contact

Brett Mass

Managing Partner, Hayden IR
[email protected]

Wize Pharma Announces Meeting Its Phase II Study Primary Objective to Demonstrate LO2A Effectively Treats Dry Eye Syndrome in Patients with Conjunctivochalasis

November 20, 2018

Wize Pharma, Inc. Announces Closing of $4.45 Million Private Placement

October 24, 2018

Wize Pharma, Inc. Announces $4.45 Million Private Placement

October 23, 2018

Wize Pharma Appoints Ellen Lubman to its Advisory Board

September 12, 2018

Wize Pharma Announces Appointment of Dr. Penny Asbell, Key Opinion Leader in Dry Eye Syndrome to Advisory Board

July 26, 2018

Wize Pharma Signs Distribution Agreement in China for LO2A

June 5, 2018

Wize Pharma Announces Presentation of New Data on LO2A in the Treatment of Dry Eye Syndrome in Patients with Sjögren’s Syndrome

May 22, 2018

Wize Pharma to Present at 3rd Annual Disruptive Growth & Healthcare Conference in New York City on May 8, 2018

May 7, 2018

Wize Pharma Completes Patient Enrollment in Phase II Study of LO2A for Treatment of Patients With CCH

April 4, 2018

Wize Pharma Enrolls First Patient in Phase IV Study of LO2A for Symptomatic Treatment of Dry Eye Syndrome in Patients With Sjögren’s Syndrome

March 28, 2018

Wize Pharma Announces Dr. Joseph Tauber, Key Opinion Leader in Dry Eye, Joins Scientific Advisory Board

March 15, 2018

Wize Pharma Announces Reverse Stock Split Effective March 5, 2018

March 5, 2018

Wize Pharma Announces Expected Exercise of Investment Rights and Warrants for Total Proceeds of $1.14 Million

February 28, 2018

Wize Pharma Receives IRB Approval of Phase IV Study Protocol for LO2A in Symptomatic Treatment of Dry Eye Syndrome in Patients With Sjögren’s Syndrome

February 20, 2018

PR 2018

Press Releases | 2018

Press Contact

Sign up to our newsletter ​

Sign up to our newsletter